<DOC>
	<DOCNO>NCT02235740</DOCNO>
	<brief_summary>This open-label , 2-part Phase I/ randomize Phase II multi-center study conduct evaluate safety , tolerability , pharmacokinetics ( PK ) , clinical activity afuresertib combination carfilzomib versus carfilzomib alone , subject relapsed/refractory MM . Part 1 evaluate 2 dose level ( 125 milligram [ mg ] 150 mg afuresertib ) 16 subject ( approximately 8 parallel arm ) determine optimal dose afuresertib administration combination carfilzomib Part 2 . If neither dose level tolerate , additional dose level 100mg afursertib combination carfilzomib may explore approximately 8 additional subject . Part 2 investigate safety , clinical activity combination afuresertib carfilzomib ( determined Part 1 ) compare carfilzomib alone , approximately 100 subject ( 50 parallel arm ) , however study terminate discontinuation single subject follow transition afuresertib development program GSK Novartis . The reason study termination protocol define study treatment longer align evolve standard care .</brief_summary>
	<brief_title>A Study Conducted Subjects With Relapsed/Refractory Multiple Myeloma ( MM ) ; Determine Dose Afuresertib Combination With Carfilzomib ( Part 1 ) Investigate Safety , Pharmacokinetic Clinical Activity Combination Compared With Carfilzomib Alone ( Part 2 )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Provided sign write informed consent , include compliance requirement restriction list consent form Histologically confirm diagnosis MM Received least two prior therapy include bortezomib immunomodulatory agent demonstrate disease progression within 60 day completion last therapy . Subjects Part 2 must also measurable disease define least one following : Serum Mprotein &gt; =0.5 gram/ deciliter ( g/dL ) ( &gt; =5 gram/Liter [ g/L ] ) , Urine Mprotein &gt; =200 mg/24 hour ( h ) , Serum free light chain ( FLC ) assay : Involved FLC level &gt; =10 mg/dL ( &gt; =100 mg/L ) abnormal serum free light chain ratio ( &lt; 0.26 &gt; 1.65 ) , Biopsy proven plasmacytoma ( measure within 28 day Screening Visit ) Male female , 18 year old Performance status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale Able swallow retain orally administer study treatment clinically significant Gastrointestinal ( GI ) abnormality may alter absorption malabsorption syndrome major resection stomach and/or bowel predispose subject GI ulceration For Alternate Arm ( 100 mg ) ( open ) , willingness undergo pair predose postdose bone marrow aspirate biopsy Fasting serum glucose &lt; 126 mg/dL ( &lt; 7 millimole/liter [ mmol/L ] ) . Subjects diagnose previously Type 2 diabetes must also meet additional follow criterion : Controlled diabetes &gt; =6 month prior enrolment , Hemoglobin A1c ( HbA1c ) = &lt; 8 % Screening visit Adequate organ system function define : Hematologic : Absolute neutrophil count ( ANC ) &gt; =1.0 X 10/meter ( ) ^9/L , Hemoglobin &gt; =8.0 g/dL , Platelets &gt; =50 X 10 m^9/L , Prothrombin time/ International normalization ratio ( PT/INR ) &lt; =1.5 ; Hepatic : Total bilirubin = &lt; 1.5 X Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5 X ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) , Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) = &lt; 1.5 X ULN , Serum Calcium correct albumin : = &lt; 12 mg/mL ( =3 mmol/L ) ; Cardiac : Corrected QT interval duration ( QTc ) interval &lt; 470 millisecond ( msec ) , Left Ventricular Ejection Fraction ( LVEF ) ( Echocardiogram [ ECHO ] Multigated acquisition scan [ MUGA ] ) &gt; =50 % , Renal : Serum Creatinine &lt; 2.5 mg/dL , Estimated glomerular filtration rate ( GFR ) 24hr urine creatinine clearance &gt; =30 mL/ minute [ min ] ( Estimated glomerular filtration rate calculate Modification Diet Renal Disease [ MDRD ] equation . When calculate 24hr creatinine clearance available , 24hr value use ) . Note : Laboratory result obtain Screening use determine eligibility criterion . In situation laboratory result outside permitted range , investigator may opt retest subject subsequent within range screen result may use confirm eligibility A female subject eligible participate Nonchildbearing potential . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method explain Investigator/designee , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential , negative serum pregnancy test within 7 day prior start study drug , screen period , agree use one contraception method explain Investigator/designee screen four week last dose afuresertib carfilzomib Male subject female partner childbearing potential must prior vasectomy agree use one contraception explain Investigator/designee . This criterion must follow time first dose study drug 10 day last dose afuresertib carfilzomib Subjects meeting follow criterion must enrol study : Prior treatment carfilzomib and/or participation Phase 3 carfilzomib trial Chemotherapy , radiotherapy , immunotherapy , antimyeloma therapy within 14 day prior first dose one drug combination regimen . In addition , drugrelated toxicity recover Grade 1 less Use investigational drug within 14 day five halflives , whichever short , precede first dose one drug combination regimen History allogeneic stem cell transplant Current use prohibit medication treatment afuresertib Current chronic use oral corticosteroid , exception inhale topical steroid Unwillingness follow lifestyle dietary restriction Evidence mucosal internal bleeding Unresolved toxicity &gt; =Grade 1 National Cancer Institute Common Terminology Criteria Adverse Events , version 4 ( NCICTCAE , 2009 ) previous anticancer therapy except alopecia &lt; =Grade 2 peripheral neuropathy Any major surgery within last four week Type 1 diabetes mellitus Any serious unstable preexist medical , psychiatric disorder , condition ( include lab abnormality ) could interfere subject 's safety , obtain informed consent compliance study procedure Impaired cardiac function clinically significant cardiac disease , include one following : Class II , III , IV heart failure define New York Heart Association functional classification system ; uncontrolled angina ; clinically significant pericardial disease ; severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker . Prior study entry , ECG abnormality Screening document investigator medically relevant . Other clinically significant ECG abnormality include second degree ( Type II ) 3rd degree atrioventricular ( AV ) block ; history myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting bypass graft within six month Screening ; pulmonary hypertension Known active infection require parenteral oral antibiotic treatment Previous concurrent malignancy allow clear tumor contribute subject 's illness . The subject must receive active therapy , hormonal therapy , disease disease must consider medically stable least 2 year . Pregnant lactating female Known Human Immunodeficiency Virus ( HIV ) infection Subjects Hepatitis B surface antigen ( HbSAg ) positive . Subjects positive test Hepatitis C ( HCV ) antibody exclude , regardless viral load . If hepatitis C antibody positive , confirmatory recombinant immunoblot assay ( RIBA ) test may perform . If RIBA test negative , subject eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Open label</keyword>
	<keyword>carfilzomib</keyword>
	<keyword>Phase I</keyword>
	<keyword>clinical activity</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>afuresertib</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>safety</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>